| __timestamp | Perrigo Company plc | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 675200000 | 612613000000 |
| Thursday, January 1, 2015 | 771800000 | 650773000000 |
| Friday, January 1, 2016 | 1205500000 | 619061000000 |
| Sunday, January 1, 2017 | 1146500000 | 628106000000 |
| Monday, January 1, 2018 | 1125800000 | 717599000000 |
| Tuesday, January 1, 2019 | 1166100000 | 964737000000 |
| Wednesday, January 1, 2020 | 1175500000 | 875663000000 |
| Friday, January 1, 2021 | 1111400000 | 886361000000 |
| Saturday, January 1, 2022 | 1210100000 | 997309000000 |
| Sunday, January 1, 2023 | 1274600000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Takeda Pharmaceutical Company Limited and Perrigo Company plc have showcased contrasting trends in their SG&A expenditures.
From 2014 to 2023, Takeda's SG&A expenses surged by approximately 72%, reflecting its aggressive expansion and strategic investments. In contrast, Perrigo's expenses grew by about 89%, indicating a steady yet controlled approach to managing operational costs. Notably, Takeda's expenses in 2023 were nearly 1,500 times higher than Perrigo's, highlighting the scale of its operations.
While Takeda's expenses peaked in 2023, Perrigo's data for 2024 remains elusive, leaving room for speculation on its future financial strategies. This analysis underscores the importance of efficient SG&A management in sustaining competitive advantage in the pharmaceutical sector.
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and argenx SE
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs BeiGene, Ltd. Trends and Insights
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Veracyte, Inc. Trends and Insights
Takeda Pharmaceutical Company Limited vs Vericel Corporation: SG&A Expense Trends
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Celldex Therapeutics, Inc.
Genmab A/S vs Perrigo Company plc: SG&A Expense Trends
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Perrigo Company plc
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Perrigo Company plc
Grifols, S.A. vs Perrigo Company plc: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Catalyst Pharmaceuticals, Inc.